Terri Parker, MD

Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet. Oncology 2020, 21: 1317-1330. PMID: 32866432, PMCID: PMC7591827, DOI: 10.1016/S1470-2045(20)30452-6.

Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia 2020, 34: 2430-2440. PMID: 32094461, PMCID: PMC7449872, DOI: 10.1038/s41375-020-0756-6.

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. The New England Journal Of Medicine 2019, 381: 727-738. PMID: 31433920, DOI: 10.1056/NEJMoa1903455.

Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 2018, 3 PMID: 29669929, PMCID: PMC5931125, DOI: 10.1172/jci.insight.98259.

Foss FM, Parker T. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.

Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 859-866. PMID: 29381435, PMCID: PMC6905485, DOI: 10.1200/JCO.2017.75.5207.

Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma, Myeloma & Leukemia 2017, 17: 296-304.e2. PMID: 28343904, PMCID: PMC5413398, DOI: 10.1016/j.clml.2017.02.025.

Barmettler S, Nowak RJ, Parker T, Price C. Previously undiagnosed fatal familial haemophagocytic lymphohistiocytosis in a 24-year-old woman. BMJ Case Reports 2016, 2016 PMID: 26903364, PMCID: PMC4769444, DOI: 10.1136/bcr-2015-213698.

Brahmandam AS, Brownson K, Skrip L, Parker T, Indes J, Sarac T, Dardik A, Chaar CI. Management of isolated calf vein thrombosis in cancer patients. Vascular 2016, 24: 64-9. PMID: 25957344, DOI: 10.1177/1708538115584726.

Bar N, Parker TL, Dhodapkar MV. Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 3689-90. PMID: 26371139, DOI: 10.1200/JCO.2015.63.2224.

Odell ID, Zeidan AM, Parker TL, Colegio OR, Subtil A. Leukaemic vasculitis with myelodysplastic syndrome. Lancet 2015, 386: 501-2. PMID: 26251396, DOI: 10.1016/S0140-6736(15)61165-5.

Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplantation 2013, 48: 646-50. PMID: 23165491, DOI: 10.1038/bmt.2012.218.

Parker T, Barbarotta L, Foss F. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma. Future Oncology (London, England) 2013, 9: 21-9. PMID: 23252560, DOI: 10.2217/fon.12.168.

Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic factors and impact on treatment. Discovery Medicine 2011, 11: 115-23. PMID: 21356166.